Stay updated on Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page
- Check3 days agoChange DetectedA new study site was added in Sfax, Tunisia (1053), expanding enrollment options. The prior Tunisia site entry (1053) was removed.SummaryDifference0.4%

- Check11 days agoChange DetectedThe page adds two NIH grant entries (2018 and 2023) and updates the revision to v3.6.6, while the previous revision v3.6.5 is removed.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe study record now lists LEO Pharma as sponsor and includes key personnel roles along with a revision tag (Revision: v3.6.5) to reflect the latest data; deletions remove older Boehringer Ingelheim data-sharing policy text and related IPD plan details from the page.SummaryDifference0.8%

- Check46 days agoChange DetectedThe study locations list was updated to include Universitätsklinikum Erlangen in Erlangen, Germany, bringing the total sites to 58, and Zenith Skin Science Center Inc. was added while Center for Skin Research, Testing and Product Development was removed.SummaryDifference0.3%

- Check66 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing v3.6.2. This reflects a minor update to the study record's documentation.SummaryDifference0.0%

- Check73 days agoChange DetectedPage revision label updated from v3.6.0 to v3.6.2, indicating a newer release of the page content. This reflects the current version shown on the page.SummaryDifference0.0%

Stay in the know with updates to Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.